NICE Rejects Kymriah for England’s NHS to Treat Aggressive DLBCL
News
Kymriah (tisagenlecleucel), developed by Novartis, has not been recommended as a treatment for adults with aggressive diffuse large B-cell lymphoma (DLBCL) for England’s National Health Service (NHS). The National Institute for Health ... Read more